| 1 |
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner et al. · Blood
Open access |
28 Nov 2016 |
5,972 |
| 2 |
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker, Moshe Talpaz, Debra J. Resta et al. · New England Journal of Medicine
Open access |
5 Apr 2001 |
5,296 |
| 3 |
The resurgence of platinum-based cancer chemotherapy
Lloyd R. Kèlland · Nature reviews. Cancer
Review |
12 Jul 2007 |
4,748 |
| 4 |
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al. · New England Journal of Medicine
Open access |
8 Jun 2016 |
4,520 |
| 5 |
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
George D. Demetri et al. · New England Journal of Medicine
Open access |
15 Aug 2002 |
4,425 |
| 6 |
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining
Janet D. Rowley · Nature
|
Jun 1973 |
4,335 |
| 7 |
Cellular processing of platinum anticancer drugs
Dong Wang, Stephen J. Lippard · Nature Reviews Drug Discovery
Review |
24 Mar 2005 |
3,802 |
| 8 |
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine
|
May 1996 |
3,681 |
| 9 |
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Stephen G. O’Brien et al. · New England Journal of Medicine
Open access |
12 Mar 2003 |
3,593 |
| 10 |
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor J. Puzanov, Kevin B. Kim et al. · New England Journal of Medicine
Open access |
25 Aug 2010 |
3,581 |
| 11 |
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature
|
27 Mar 2005 |
3,573 |
| 12 |
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William J. Pao, Vincent A. Miller, Katerina A. Politi et al. · PLoS Medicine
Open access |
17 Feb 2005 |
3,557 |
| 13 |
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Brian J. Druker et al. · New England Journal of Medicine
Open access |
6 Dec 2006 |
3,508 |
| 14 |
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Döhner, Elihu H. Estey, Sergio Amadori et al. · Blood
Open access |
30 Oct 2009 |
3,422 |
| 15 |
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine
|
28 Dec 2000 |
3,318 |
| 16 |
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Mercedes E. Gorre, Mansoor Mohammed, Katharine B. Ellwood et al. · Science
|
3 Aug 2001 |
3,120 |
| 17 |
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Ross L. Levine et al. · Cancer Cell
Open access |
Apr 2005 |
3,023 |
| 18 |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al. · The Lancet
|
25 Jun 2012 |
3,009 |
| 19 |
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Brian J. Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine
Open access |
5 Apr 2001 |
2,735 |
| 20 |
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson, John M. Bennett, Kenneth J. Kopecky et al. · Journal of Clinical Oncology
|
12 Dec 2003 |
2,682 |
| 21 |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Maury Stone et al. · New England Journal of Medicine
Open access |
23 Jun 2017 |
2,258 |
| 22 |
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Pierangelo Palumbo et al. · Journal of Clinical Oncology
Open access |
3 Aug 2015 |
2,243 |
| 23 |
Induction of Chronic Myelogenous Leukemia in Mice by the P210 bcr/abl Gene of the Philadelphia Chromosome
George Q. Daley, Richard A. Van Etten, David Baltimore · Science
Open access |
16 Feb 1990 |
2,196 |
| 24 |
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al. · New England Journal of Medicine
Open access |
Mar 2017 |
2,162 |
| 25 |
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
Heikki Joensuu, Peter James Joseph Roberts, Maarit Sarlomo‐Rikala et al. · New England Journal of Medicine
Open access |
5 Apr 2001 |
2,061 |
| 26 |
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine
Open access |
28 Feb 2002 |
2,041 |
| 27 |
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice Tsang Shaw et al. · New England Journal of Medicine
Open access |
27 Sep 2014 |
2,013 |
| 28 |
Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.
T. R. Breitman, Stuart E. Selonick, SJ Collins · Proceedings of the National Academy of Sciences
Open access |
May 1980 |
2,008 |
| 29 |
DNMT3A Mutations in Acute Myeloid Leukemia
Timothy James Ley et al. · New England Journal of Medicine
Open access |
10 Nov 2010 |
2,007 |
| 30 |
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al. · Blood
Open access |
27 Jun 2013 |
2,005 |
| 31 |
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]
HJ Kolb, Anton V. M. B. Schattenberg, JM Goldman et al. · Blood
Open access |
Sep 1995 |
1,974 |
| 32 |
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al. · New England Journal of Medicine
Open access |
14 Mar 2012 |
1,971 |
| 33 |
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew Warwick Roberts, Matthew Steven Davids, John M. Pagel et al. · New England Journal of Medicine
Open access |
6 Dec 2015 |
1,929 |
| 34 |
A small molecule–kinase interaction map for clinical kinase inhibitors
Miles A. Fabian et al. · Nature Biotechnology
Open access |
13 Feb 2005 |
1,927 |
| 35 |
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A. Hilary Calvert, David R. Newell, Lindsey A. Gumbrell et al. · Journal of Clinical Oncology
|
Nov 1989 |
1,893 |
| 36 |
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al. · Blood
Open access |
12 Sep 2013 |
1,863 |
| 37 |
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science
|
15 Jul 2004 |
1,811 |
| 38 |
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Thomas Hellmut Schindler, William G. Bornmann, Patricia Pellicena et al. · Science
|
15 Sep 2000 |
1,799 |
| 39 |
The Conformational Plasticity of Protein Kinases
Morgan Huse, John Kuriyan · Cell
Open access |
May 2002 |
1,794 |
| 40 |
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine
Open access |
14 Jun 2006 |
1,789 |
| 41 |
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood
Open access |
15 Jun 2002 |
1,749 |
| 42 |
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Scott A. Armstrong, Jane E. Staunton, Lewis B. Silverman et al. · Nature Genetics
|
3 Dec 2001 |
1,732 |
| 43 |
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine
Open access |
5 Jun 2010 |
1,691 |
| 44 |
Doxorubicin pathways
Caroline F. Thorn, Connie M. Oshiro, Sharon Marsh et al. · Pharmacogenetics and Genomics
Open access |
4 Nov 2010 |
1,663 |
| 45 |
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd et al. · New England Journal of Medicine
Open access |
31 May 2014 |
1,649 |
| 46 |
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang et al. · Nature
Open access |
2012 |
1,643 |
| 47 |
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
Emma Shtivelman, Batia Lifshitz, Robert Peter Gale et al. · Nature
|
Jun 1985 |
1,641 |
| 48 |
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk, Konstanze Döhner, Jürgen Krauter et al. · New England Journal of Medicine
|
30 Apr 2008 |
1,641 |
| 49 |
Chronic Myeloid Leukemia
Charles L. Sawyers · New England Journal of Medicine
|
29 Apr 1999 |
1,638 |
| 50 |
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Neil P. Shah, John M. Nicoll, Bhushan Nagar et al. · Cancer Cell
Open access |
Aug 2002 |
1,635 |